Clinical Trial Update: Effect of Esketamine on Postoperative Depression、Gut Microbiota、Bispectral Index Data of Depression Patients Undergoing Breast Cancer Operation (ESPOD-BI) [Phase 4]

View source ↗

Summary

Phase 4 study ESPOD-BI assesses esketamine's impact on postoperative depression, gut microbiota changes, and BIS readings in patients with depression undergoing…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• SPRAVATO (ESKETAMINE HYDROCHLORIDE)

Snippet

Sponsor: China Medical University, China | Conditions: Depression | Phase 4 | Status: RECRUITING